Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Biogen Inc.

NASDAQ

Market Cap.

33.57B

Avg. Volume

1.25M

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Biogen Inc.!

Still processing it, give me a bit more time...

Biogen Inc. News

Biogen Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Website screenshot
HealthcareDrug Manufacturers - General
biogen.com

About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc. Earnings & Revenue

Biogen Inc. Financials

Table Compare

Compare BIIB metrics with:

   

Earnings & Growth

BIIB

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

BIIB

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

BIIB

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

BIIB

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Biogen Inc. Income

Biogen Inc. Balance Sheet

Biogen Inc. Cash Flow

Biogen Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityBuy
Return on AssetsBuy
Debt/Equity RatioBuy
Price/Earnings RatioBuy
Price/Book RatioNeutral

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Biogen Inc. Executives

NameRole
Mr. Christopher A. ViehbacherPresident, Chief Executive Officer & Director
Mr. Michael R. McDonnell CPAExecutive Vice President & Chief Financial Officer
Ms. Susan H. Alexander Esq.Executive Vice President & Chief Legal Officer
Dr. Ginger Gregory Ph.D.Executive Vice President & Chief Human Resources Officer
Ms. Nicole MurphyHead of Pharmaceutical Operations & Technology
NameRoleGenderDate of BirthPay
Mr. Christopher A. ViehbacherPresident, Chief Executive Officer & DirectorMale19614.07M
Mr. Michael R. McDonnell CPAExecutive Vice President & Chief Financial OfficerMale19642.21M
Ms. Susan H. Alexander Esq.Executive Vice President & Chief Legal OfficerFemale19571.95M
Dr. Ginger Gregory Ph.D.Executive Vice President & Chief Human Resources Officer19681.59M
Ms. Nicole MurphyHead of Pharmaceutical Operations & TechnologyFemale19731.45M

Biogen Inc. Insider Trades

Date1 May
NameKeeney Adam
RoleHead of Corporate Development
TransactionAcquired
TypeM-Exempt
Shares938
Date1 May
NameKeeney Adam
RoleHead of Corporate Development
TransactionDisposed
TypeF-InKind
Shares276
Date1 May
NameKeeney Adam
RoleHead of Corporate Development
TransactionDisposed
TypeM-Exempt
Shares938
Date2 Apr
NameSinghal Priya
RoleHead of Development
TransactionDisposed
TypeS-Sale
Shares93
Date1 Apr
NameMurphy Nicole
RoleHead of Pharm Ops and Tech
TransactionAcquired
TypeM-Exempt
Shares240
DateNameRoleTransactionTypeShares
1 MayKeeney AdamHead of Corporate DevelopmentAcquiredM-Exempt938
1 MayKeeney AdamHead of Corporate DevelopmentDisposedF-InKind276
1 MayKeeney AdamHead of Corporate DevelopmentDisposedM-Exempt938
2 AprSinghal PriyaHead of DevelopmentDisposedS-Sale93
1 AprMurphy NicoleHead of Pharm Ops and TechAcquiredM-Exempt240

Discover More

Streamlined Academy

Biogen Inc.

NASDAQ

Market Cap.

33.57B

Avg. Volume

1.25M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Biogen Inc. News

Biogen Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Biogen Inc. Earnings & Revenue

Biogen Inc. Income

Biogen Inc. Balance Sheet

Biogen Inc. Cash Flow

Biogen Inc. Financials Over Time

Biogen Inc. Executives

NameRole
Mr. Christopher A. ViehbacherPresident, Chief Executive Officer & Director
Mr. Michael R. McDonnell CPAExecutive Vice President & Chief Financial Officer
Ms. Susan H. Alexander Esq.Executive Vice President & Chief Legal Officer
Dr. Ginger Gregory Ph.D.Executive Vice President & Chief Human Resources Officer
Ms. Nicole MurphyHead of Pharmaceutical Operations & Technology
NameRoleGenderDate of BirthPay
Mr. Christopher A. ViehbacherPresident, Chief Executive Officer & DirectorMale19614.07M
Mr. Michael R. McDonnell CPAExecutive Vice President & Chief Financial OfficerMale19642.21M
Ms. Susan H. Alexander Esq.Executive Vice President & Chief Legal OfficerFemale19571.95M
Dr. Ginger Gregory Ph.D.Executive Vice President & Chief Human Resources Officer19681.59M
Ms. Nicole MurphyHead of Pharmaceutical Operations & TechnologyFemale19731.45M

Biogen Inc. Insider Trades

Date1 May
NameKeeney Adam
RoleHead of Corporate Development
TransactionAcquired
TypeM-Exempt
Shares938
Date1 May
NameKeeney Adam
RoleHead of Corporate Development
TransactionDisposed
TypeF-InKind
Shares276
Date1 May
NameKeeney Adam
RoleHead of Corporate Development
TransactionDisposed
TypeM-Exempt
Shares938
Date2 Apr
NameSinghal Priya
RoleHead of Development
TransactionDisposed
TypeS-Sale
Shares93
Date1 Apr
NameMurphy Nicole
RoleHead of Pharm Ops and Tech
TransactionAcquired
TypeM-Exempt
Shares240
DateNameRoleTransactionTypeShares
1 MayKeeney AdamHead of Corporate DevelopmentAcquiredM-Exempt938
1 MayKeeney AdamHead of Corporate DevelopmentDisposedF-InKind276
1 MayKeeney AdamHead of Corporate DevelopmentDisposedM-Exempt938
2 AprSinghal PriyaHead of DevelopmentDisposedS-Sale93
1 AprMurphy NicoleHead of Pharm Ops and TechAcquiredM-Exempt240

Streamlined Academy

Website screenshot
HealthcareDrug Manufacturers - General
biogen.com

About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Biogen Inc.!

Still processing it, give me a bit more time...

Biogen Inc. Financials

Table Compare

Compare BIIB metrics with:

   

Earnings & Growth

BIIB

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

BIIB

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

BIIB

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

BIIB

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Biogen Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsBuy
Return on EquityBuy
Return on AssetsBuy
Debt/Equity RatioBuy
Price/Earnings RatioBuy
Price/Book RatioNeutral

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More